Najim R A, Farid Y Y Z, Samad T Abed, Shihab S A R
Department of Pharmacology, College of Medicine, University of Baghdad, Baghdad, Iraq.
East Mediterr Health J. 2005 Sep-Nov;11(5-6):1003-8.
The study was designed to determine the acetylator status in patients with systemic lupus erythematosus (SLE) and compare it to a matched group of healthy volunteers. Disease severity was determined using the revised American College of Rheumatology criteria for classification and the SLE disease activity index. After an overnight fast, each participant received a single oral dose of 100 mg dapsone. After 3 hours, plasma dapsone/monoacetyldapsone ratio was determined. In the control group, frequency of slow acetylators was 73.3%; frequency of rapid acetylators was 26.7%. In SLE patients, frequency of slow acetylators was 78.0%; frequency of rapid acetylators was 12.0%. However, 8.0% were non-acetylators (monoacetyldapsone not detected in plasma). There was no association between acetylator status and severity of SLE.
该研究旨在确定系统性红斑狼疮（SLE）患者的乙酰化状态，并将其与一组匹配的健康志愿者进行比较。使用修订后的美国风湿病学会分类标准和SLE疾病活动指数来确定疾病严重程度。在禁食过夜后，每位参与者口服一剂100毫克氨苯砜。3小时后，测定血浆氨苯砜/单乙酰氨苯砜比值。在对照组中，慢乙酰化者的频率为73.3%；快乙酰化者的频率为26.7%。在SLE患者中，慢乙酰化者的频率为78.0%；快乙酰化者的频率为12.0%。然而，8.0%为非乙酰化者（血浆中未检测到单乙酰氨苯砜）。乙酰化状态与SLE的严重程度之间没有关联。
